Bausch + Lomb is a global eye health company with a diverse and comprehensive portfolio of vision care, consumer health care, surgical and pharmaceutical products.
With a commitment to the development and marketing of eye health products, Bausch + Lomb has established and oversees an effective and comprehensive compliance program in accordance with federal, state and industry guidelines including the “Compliance Program Guidance for Pharmaceutical Manufacturers,” published by the Office of Inspector General (“OIG”), U.S. Department of Health and Human Services, the Pharmaceutical Research and Manufacturers of America’s (“PhRMA”) “Code of Interactions with Healthcare Professionals” and the Advanced Medical Technology Association (“AdvaMed”) “Code of Ethics on Interactions with Health Care Professionals”.
There has been a significant amount of effort and resources that have been dedicated to implementing a Comprehensive Compliance Program (CCP) at Bausch + Lomb, including checks and balances to prevent and detect violations of law or Company policy.
Key elements of the Bausch + Lomb Compliance Program include:
Bausch + Lomb is a global eye health company with a diverse and comprehensive portfolio of vision care, consumer health care, surgical and pharmaceutical products.
With a commitment to the development and marketing of eye health products, Bausch + Lomb has established and oversees an effective and comprehensive compliance program in accordance with federal, state and industry guidelines including the “Compliance Program Guidance for Pharmaceutical Manufacturers,” published by the Office of Inspector General (“OIG”), U.S. Department of Health and Human Services, the Pharmaceutical Research and Manufacturers of America’s (“PhRMA”) “Code of Interactions with Healthcare Professionals” and the Advanced Medical Technology Association (“AdvaMed”) “Code of Ethics on Interactions with Health Care Professionals”.
There has been a significant amount of effort and resources that have been dedicated to implementing a Comprehensive Compliance Program (CCP) at Bausch + Lomb, including checks and balances to prevent and detect violations of law or Company policy.
Key elements of the Bausch + Lomb Compliance Program include:
We rely on the feedback and expertise of health care professionals to help us better develop and promote our products. That is why it is our responsibility to fairly and transparently compensate for time and services, including:
We are grateful to our health care collaborators who help us deliver on our mission to help millions across the globe to see better and live better.
Please note that we do not compensate health care professionals for prescribing or recommending our products.
We value ongoing education for health care professionals and independent research that aims to improve patient outcomes and lives.
The grants we offer to educational organizations, physicians and clinical institutions are intended to support independent scientific research and are not affiliated with our brand or internal research and development.
All of our grantees must be compliant with federal and state laws and, to the extent applicable, American Academy of Continuing Medical Education standards.
We are committed to maintaining the highest ethical standards and complying with all U.S. laws and regulations regarding marketing, promotion and education around our health care products.
Per California Health and Safety Code §§ 119402, we have adopted a CCP that is in accordance with the April 2003 publication, “Compliance Program Guidance for Pharmaceutical Manufacturers,” developed by the United States Department of Health and Human Services Office of Inspector General (OIG).
As the OIG publication states, it is difficult to eliminate the possibility of an individual employee breaching our company policy. However, our CCP has designated multiple processes to detect and avoid such instances.
We ensure that our CCP will reflect any updates or revisions made to the OIG publication within six months of the effective date. Additionally, we will continue to reevaluate CCP guidelines and practices annually and as pharmaceutical regulation and legislation evolve.
The Declaration is effective from January 1, 2023 to December 31, 2023. The CCP is a fluid and ever-changing program that is designed to meet the evolving regulatory and legislative climate. This program will be assessed on an annual basis.
Please click here to review the Declaration.
A copy of this Declaration can be obtained by calling the toll-free number 1-844-974-5090.
Through our CCP, we ensure that our research, education, marketing and sales efforts continue to perform at the highest level of U.S. health care ethical and regulatory standards.
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.